Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694350 | 0.89 | KDM4E (0.61) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL694024 | 0.83 | NPC1 (0.57) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL29941393 | 0.79 | APP (0.54) | SMN1; SMN2MAPTGAAAPPHTT | |
| SCHEMBL121577 | 0.76 | KDM4E (0.81) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL1638045 | 0.76 | CDK5 (0.60) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL14415813 | 0.74 | KDM4E (0.80) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL23409082 | 0.73 | NPC1 (0.52) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL121976 | 0.73 | RAB9A (0.52) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL6979665 | 0.73 | NPC1 (0.72) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL13412996 | 0.73 | NPC1 (0.49) | CDK5CDK5R1KDM4ESMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | disclosed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8623858-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130137674-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123233-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130123233-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130137674-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CDK5 3940/4885CDK5R1 3451/4885KDM4E 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.